FENC Stock Analysis: Buy, Sell, or Hold?
FENC - Fennec Pharmaceuticals Inc. Common Stock
$10.30
0.77 (8.08%)
▲
5d:
+12.08%
30d:
+3.31%
90d:
+38.26%
BUY
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 13, 2026
Get Alerted When FENC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: FENC shows positive signals but monitor for confirmation. Market pricing in 4.2% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: FENC shows positive signals but monitor for confirmation. Market pricing in 4.2% annual growth which appears achievable. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$17.68
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$10.98
6.2% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 10.2x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: FENC is currently trading at $10.30, which is considered extended relative to its 30-day fair value range of $8.94 to $9.93. From a valuation perspective, the stock is trading at a premium (Forward PE: 11.6) compared to its historical average (10.2). At these levels, the market is pricing in 4.2% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, FENC is showing sideways momentum. The price is approaching resistance at $10.28. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 8.1% recently.
Market Sentiment: FENC has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $15.67 (+52.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, FENC is showing sideways momentum. The price is approaching resistance at $10.28. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 8.1% recently.
Market Sentiment: FENC has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $15.67 (+52.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$8.94 -
$9.93
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
67.6%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+8.1%)
- BULLISH: Trading 52.1% below Wall St target ($15.67)
- NEUTRAL: Market pricing in 4.2% annual earnings growth - fairly valued
Trading Range Analysis
30-Day Trading Range
$8.94 -
$9.93
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$8.57
Resistance Level
$10.28
Current Trend
Sideways
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
11.57
Wall Street Target
$15.67
(+52.1%)
Revenue Growth (YoY)
72.6%
Profit Margin
-16.4%
Valuation Premium vs History
+4.2% premium
PE vs Historical
11.6 vs 10.2
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+4.2%
(market-implied from PE analysis)
1-Year Target
$10.73
(+4%)
2-Year Target
$11.18
(+9%)
3-Year Target
$11.65
(+13%)
3-Yr Target (if PE normalizes)
(PE: 12→10)
PE COMPRESSION
$10.27
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 200.7%)
$65.42
(+535%)
Base:
(SPY PE: 11.6, Growth: 200.7%)
$34.76
(+238%)
Bear:
(PE: 9.8, Growth: 200.7%)
$29.55
(+187%)
Share & Embed Analysis
Last updated: June 24, 2026 4:00 AM ET
Data refreshes hourly during market hours. Next update: 5:00 AM
Data refreshes hourly during market hours. Next update: 5:00 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is FENC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Rosty Raykov
SELL
10946 shares
2026-04-01
Rosty Raykov
SELL
10349 shares
2026-02-02
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 56 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 57 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1022 | 67 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 61 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
